Single-Use Bioprocessing Market Size Will Attain USD 84.12 BN By 2030

November 1, 2022 |

8 min read

The Global Single-Use Bioprocessing Market Size accounted for USD 21.98 Billion in 2021 and is estimated to achieve a market size of USD 84.12 Billion by 2030 growing at a CAGR of 16.1% from 2022 to 2030.

The Global Single-Use Bioprocessing Market Size accounted for USD 21.98 Billion in 2021 and is estimated to achieve a market size of USD 84.12 Billion by 2030 growing at a CAGR of 16.1% from 2022 to 2030.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/6115

Single-Use Bioprocessing Market Size 2022 to 2030

The demand for single-use bioprocessing offerings is driven by the commercial advantages offered, including a reduction in costs and time required for bioprocessing operations. Originally used for monoclonal antibody production, single-use technologies are also gaining traction for cell and gene therapy manufacturing. As a result, broadening the scope of applications in biomanufacturing operations is likely to drive industry growth.

Furthermore, strategic initiatives from key players are expanding the industry’s growth prospects. For instance, in July 2021, Cytiva and Pall Corp. announced investment plans for capacity expansion over two years. Among other key products, more than USD 300 million were invested in single-use technologies, such as bioreactor bags for cell expansion, used to make personalized therapies and syringe filters for scientific research. Similarly, the growing adoption of single-use equipment for in-house and contract manufacturing has opened new avenues for the flow of investments in this space. The industry is witnessing significant advancements in several product portfolios, including disposable probes and sensors, stirring systems, bioreactor designs, and filtration technologies, which are expected to contribute to strong revenue growth.

The benefits offered by single-use bioprocessing systems have enabled biopharmaceutical manufacturers to offer their products faster to the market by introducing multi-product facilities, entering into partnerships, or outsourcing pipeline products for contract development and manufacturing. For instance, in January 2021, Sartorius AG partnered with RoosterBio, a leading supplier of human Mesenchymal Stem/Stromal Cells (hMSC). This collaboration aimed at advancing cell & gene therapy manufacturing by leveraging the single-use manufacturing technologies from Sartorius AG. The COVID-19 pandemic has generated new growth opportunities for key stakeholders in the industry.

Key biopharmaceutical players can leverage the opportunity by expanding their COVID-19-related product offerings by scaling up their production facilities with the implementation of single-use bioprocessing equipment. A significant number of biopharmaceutical companies are actively involved in the development and production of COVID-19 vaccines. These programs are majorly based on single-use technologies as these systems are flexible, cost-effective, and reduce the risk of cross-contamination. Such an ongoing and continuous increase in the adoption of bioprocessing systems due to the COVID-19 pandemic is anticipated to drive industry growth.

Report Coverage

Report Scope	Details
Market Size	USD 84.12 billion by 2030
Growth Rate	CAGR of 16.1% From 2022 to 2030
Base Year	2021
Forecast Period	2022 to 2030
Report coverage	Growth Factors, Revenue Status, Competitive Landscape, and Future Trends
Segments Covered	Product, End User, Application, Workflow, Region

Ask here for more customization study@

Single-use Bioprocessing Market Report Highlights

The simple & peripheral elements segment held the largest share in 2021 due to the significant adoption of these products as a result of a variety of customizable options available for bioprocessing applications
The upstream bioprocessing workflow segment accounted for the largest share in 2021. Continuous developments and betterment in technologies for upstream bioprocessing are driving the segment growth
North America was the leading region in 2021 due to the high R&D spending and growth of the biopharmaceutical manufacturing sector in the region
Furthermore, the presence of key players, such as Thermo Fisher Scientific, Inc. and Danaher Corp., is driving the regional market
The biopharmaceutical manufacturer’s end-use segment dominated the industry in 2021 and accounted for the maximum revenue share. This was due to the high demand for biologics and heavy investments in cell & gene therapy manufacturing

Global Single use Bioprocessing Market Dynamics

DRIVER:

According to the UN Ageing population highlights, in 2020, an estimated 730 million individuals of the global population was aged 65 years and older; by 2050, this figure is estimated to double and reach 1.9 billion individuals. With a growth in the senior population across major markets, the demand for biopharmaceuticals is expected to increase as the elderly are more prone to chronic conditions & diseases. To cater to the growing demand for biopharmaceuticals, companies are increasingly preferring single-use bioprocessing systems as they increase process efficiency and decrease the costs associated with complicated steps like cleaning, sterilization, and maintenance of steel-based bioreactor systems.

RESTRAINT:

Specific guidelines or regulations regarding the contamination of single-use bioprocessing systems due to extractables and leachables are not yet established. However, a complete list of tests that can be performed for single-use systems has been published by the Bio-Process Systems Alliance (BPSA). Extractables can be extracted from source materials using appropriate solvents under vigorous laboratory conditions.

OPPORTUNITY:

In the Asian region, China is a high-potential market for single-use bioprocessing systems, followed by India. This can majorly be attributed to the presence of favorable government support, rising private investments, growing geriatric population, rising trend of outsourcing to emerging Asian markets, and presence of a skilled workforce in these countries. India, Japan, Brazil, and RoAPAC are expected to be the new revenue pockets for market players. Also, the high investment in bio-manufacturing infrastructure is a key factor responsible for the high-growth potential of these markets.

CHALLENGE:

Biopharmaceutical companies are increasingly adopting single-use bioprocessing systems considering the several associated advantages, such as cost reduction, faster process development time, and lower capital investments. However, there still are serious concerns related to the disposal of solid waste materials from this alternative technology. Recycling is not an option for such products because they require extensive efforts to separate the components into homogeneous components. As a result, most single-use systems and their components are not suited for recycling.

Regional Insights

Based on the region, the North America dominated the market in 2020 with revenue share of 34% and is estimated to be the most opportunistic market. This is attributed to the rapid growth and development of biopharmaceutical industry in the region. Moreover, the outbreak of the COVID-19 pandemic stimulated the government to invest heavily in the research and development of the COVID-19 vaccines, diagnostics tests, and drugs. The US government sanctioned over US$ 480 million to Moderna, Inc., for the development of COVID-19 vaccines. The Canada government spent around US$ 160 million in 2020, towards the development of vaccines and drugs for COVID-19 treatment.

The presence of giant players, largescale production units, growing adoption of disposables, increased expenditure in health care, and highly developed healthcare infrastructure are the top factors augmenting the North America single-use bioprocessing market. Moreover, the numerous contract manufacturers and the growing usage of disposables amongst them is exponentially driving the single-use bioprocessing market in the region.

The Asia Pacific has potential growth opportunities owing to the growing biopharmaceutical market in the nations such as China, Japan, and India. Moreover, rising investments by the biotechnology and pharmaceutical companies and the rapid growth of the contract manufacturers may lead to the emergence of Asia Pacific to be the manufacturing hub for the pharmaceuticals. Hence, the region may contribute significantly towards the growth of the single-use bioprocessing market in the forthcoming years.

Some of the prominent players in the Single-Use Bioprocessing Market include:

Thermo Fisher Scientific, Inc.
Sartorius AG
Merck KGaA
Pall Corporation
Corning Incorporated
Eppendorf AG
General Electric Company (GE Healthcare)
Lonza
Rentschler Biopharma SE
JM BioConnect
Meissner Filtration Products, Inc.
Infors AG
BoehringerIngelheim GmbH
Entegris, Inc.
PBS Biotech, Inc.

Segments Covered in the Report

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:

Segments Covered in the Report

By Product